FDA approves ETCAMAH — Astrazeneca Pharmaceuticals, Lp
Why it matters
A new molecular entity approval adds a pipeline asset for AstraZeneca but no revenue figures are given.
Details
NDA220359 original application approved 2026-09-04. Sponsor: Astrazeneca Pharmaceuticals, Lp. Product: ETCAMAH. Review: Standard. Class: Type 1 - New Molecular Entity. Source: openFDA Drugs@FDA.
Sources
- openfda · accessdata.fda.gov · 2026-09-04 12:00 UTC